4//SEC Filing
Vitae Pharmaceuticals, Inc 4
Accession 0001104659-16-151938
CIK 0001157602operating
Filed
Oct 24, 8:00 PM ET
Accepted
Oct 25, 4:31 PM ET
Size
19.0 KB
Accession
0001104659-16-151938
Insider Transaction Report
Form 4
Morris Richard Steven
Chief Financial Officer
Transactions
- Disposition to Issuer
Common Stock
2016-10-25$21.00/sh−828$17,388→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2016-10-25$15.71/sh−152,173$2,390,638→ 0 totalExercise: $5.29Exp: 2024-06-24→ Common Stock (152,173 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2016-10-25$6.60/sh−15,000$99,000→ 0 totalExercise: $14.40Exp: 2025-02-13→ Common Stock (15,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2016-10-25$12.72/sh−15,000$190,800→ 0 totalExercise: $8.28Exp: 2025-08-14→ Common Stock (15,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2016-10-25$12.42/sh−27,500$341,550→ 0 totalExercise: $8.58Exp: 2026-02-15→ Common Stock (27,500 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2016-10-25$12.22/sh−27,500$336,050→ 0 totalExercise: $8.78Exp: 2026-08-14→ Common Stock (27,500 underlying)
Footnotes (7)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., whereby, immediately prior to the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were converted into the right to receive $21.00 per share in cash and, when so converted, automatically cancelled.
- [F2]Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option.
- [F3]This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on May 19, 2014 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
- [F4]This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the "February 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
- [F5]This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the "August 2016 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
- [F6]This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the "February 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
- [F7]This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the "August 2017 Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Documents
Issuer
Vitae Pharmaceuticals, Inc
CIK 0001157602
Entity typeoperating
Related Parties
1- filerCIK 0001157602
Filing Metadata
- Form type
- 4
- Filed
- Oct 24, 8:00 PM ET
- Accepted
- Oct 25, 4:31 PM ET
- Size
- 19.0 KB